

Rgenta Therapeutics to Participate Upcoming TD Cowen 44th Annual Health Care Conference (March 4th 2024)

CAMBRIDGE, Mass., Feb 26th, 2024 - Rgenta Therapeutics (“Rgenta” or the “Company”) is developing a pipeline of oral, small-molecule RNA-targeting medicines with lead programs in IND enabling stage targeting root causes of oncology and neurological disorders. Rgenta will participate the TD Cowen 44th Annual Health Care Conference on March 4th 2024 and host one-on-one meetings with investors. Please contact your TD Cowen representative if interested in scheduling a meeting with the Rgenta management team.

About Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at www.rgentatx.com.